Genetic variants cause arthritis in a certain subset of women when they take aromatase inhibitors for breast cancer.
This serious side effect is so painful that many women halt their lifesaving medication.
"Many women stop taking aromatase inhibitors due to the accompanying joint pain," said Dr. James Ingle, Mayo Clinic oncologist and senior author of the study.
Aromatase inhibitors are most often used as adjuvant therapy for postmenopausal women with early stage breast cancer.
The researchers -- including investigators from the United States, Canada and Japan-conducted a genome-wide association study to identify gene variants called single nucleotide polymorphisms (SNPs) that are associated with musculoskeletal pain.
They selected patients who were enrolled in a prospective clinical trial, MA27, conducted by the NCIC Clinical Trials Group in Canada in collaboration with the NCI-sponsored North American Breast Cancer Groups comparing two aromatase inhibitor drugs.
Two controls were matched with each patient and each patient who was selected experienced arthritis-like side effects within the first two years of treatment, or had already dropped out of the trial because of the pain.
Researchers studied 293 separate cases, comparing them to 585 controls.
They found four likely SNPs on chromosome 14, all of which were nearest the gene T-Cell Leukemia 1A, which they discovered also was estrogen dependent.
One of the SNPs also created an estrogen response with increased gene expression after exposure to estradiol, a widely used post-menopausal treatment.
The results provide researchers with genetic markers for the aromatase inhibitor-induced arthritis and clues to find ways to treat it.
The findings appear in the online issue of Journal of Clinical Oncology.